The drug company Eli Lilly is suing four telehealth companies for allegedly selling copies made by compounding pharmacies of ...

In its continuing war against copycat drugs, Eli Lilly (LLY) said on Wednesday that it filed suits against four telehealth ...

Eli Lilly’s legal actions against Empower Pharmacy and other compounding pharmacies come several months after the FDA ...

Eli Lilly suit against Houston’s Empower Pharmacy is a battle over access to a multi-billion dollar market for weight loss ...

In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – Research Report). The company’s shares closed yesterday at $726.24.

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly ... of select Lilly medicines, including Zepbound, through third-party pharmacy ...

On this episode of Stock Movers: - Eli Lilly (LLY) shares slump while large US and European drugmakers slide, underperforming amid a broad market slump, after President Donald Trump said the US wa ...

One of them is the pharmaceutical industry. However, some major executives in the sector are not optimistic, including Eli Lilly's (NYSE: LLY) CEO, David Ricks. Start Your Mornings Smarter!

April 8 - Eli Lilly (NYSE:LLY) shares rose about 5% Tuesday morning after Goldman Sachs (NYSE:GS) upgraded the pharmaceutical giant to Buy from Neutral, citing confidence in its leadership in the fast ...

INDIANAPOLIS — Eli Lilly and Company says it's suing an Indianapolis-based weight loss clinic that it claims is misleading patients about drugs being sold. Lilly claims Premier Weight Loss is selling ...

On Tuesday, Goldman Sachs upgraded shares of Eli Lilly (NYSE:LLY) from Neutral to Buy, while slightly reducing the price target to $888 from $892. The firm's analyst highlighted the pharmaceutical ...